ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 222
- Registration Number
- NCT00507455
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2011-03-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 156
- Registration Number
- NCT00505037
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 41
- Registration Number
- NCT00498914
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 43
- Registration Number
- NCT00493324
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 403
- Registration Number
- NCT00487682
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 695
- Registration Number
- NCT00486200
A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 240
- Registration Number
- NCT00481819
- Locations
- 🇨🇳
2 Sites, Shanghai, Shanghai, China
🇨🇳3 Sites, Beijing, Beijing, China
Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 346
- Registration Number
- NCT00481481
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 250
- Registration Number
- NCT00480896
- Locations
- 🇨🇿
3 Sites, Praha, Czech Republic
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 226
- Registration Number
- NCT00480610
© Copyright 2024. All Rights Reserved by MedPath